Haier Biomedical was founded to focus on the research & development, manufacturing, and sales of low-temperature storage equipment for biomedical samples. Based on the concept of IoT, the company has become a digital scenario solution provider in life science and medical innovation. Aiming at creating the best user experience, the company mainly engages in life science and medical innovation and delivers comprehensive digital scenario solutions covering multiple categories of products and services, such as smart lab, digital hospital, smart public health, smart blood use, to a wide range of user groups, including hospitals, bio-pharmaceutical enterprises, universities & colleges, scientific research institutions, centers for disease control, and blood stations.

Since 2005, Haier Biomedical has been dedicated to promoting technological innovation and leading the industry as a technology leader. By developing biomedical cryogenic technology, the company has become a new international manufacturer in the global market. As a result, the company won the China's only National Prize for Progress in Science and Technology, within this industry, and participated in creating 32 national, industry, and group standards to promote the standardized development of the industry. To stay competitive in the digital economy era, Haier Biomedical has integrated IoT, automation, and other emerging technologies, and launched comprehensive digital scenario solutions, such as smart blood use and smart vaccination. The company also pioneered in-hospital medication automation, digital public health, physical examination, and other scenario solutions, leading the transformation of the biomedical industry. Haier Biomedical has continuously made innovations in microbial culture, environmental simulation, rapid refrigerated centrifuges, and surface modification of high polymer materials. By emphasizing smart labs and other comprehensive scenario solutions, the company has expanded its influence in life sciences and medical innovation.

By the end of 2022, the company has obtained a total of 795 patents, including 114 software copyright, and 131 new applications for inventions were proposed in that current year. The company has gained 20 provincial and above science and technology awards cumulatively, including First Prize of Shandong Provincial Prize for Progress in Science and Technology, and First Prize in Science and Technology of China Society for the Promotion of Science and Technology Commercialization, and has been listed into the National Champion Enterprises in Manufacturing Industry, the National List of Big Data Industry Development Pilot Demonstration Projects, etc. On the life science and medical innovation track, Haier Biomedical keeps occupying the commanding heights of scientific and technological innovation and leading the high-quality development of the industry.

By the end of 2022, Haier Biomedical had acquired a total of 795 patents, including 114 software copyrights. In that year alone, the company proposed 131 new applications for inventions. The company has also received 20 provincial and above science and technology awards, including the First Prize of the Shandong Provincial Prize for Progress in Science and Technology and the First Prize in Science and Technology of the China Society for the Promotion of Science and Technology Commercialization. Additionally, the company has been listed in the National Champion Enterprises in Manufacturing Industry and the National List of Big Data Industry Development Pilot Demonstration Projects. Haier Biomedical continues to lead the high-quality development of the industry, occupying the commanding heights of scientific and technological innovation in the field of life science and medical innovation.

Haier Biomedical's products and solutions have been utilized in over 135 countries and regions worldwide and has established over 700 overseas distribution networks, expanding all the time. Haier Biomedical has formed partnerships with more than 40 international organizations such as the World Health Organization (WHO), the United Nations International Children's Emergency Fund (UNICEF), and the United Nations Global Compact (UNGC). The company has established experience and training centers in Dubai, Nigeria, Singapore, and the UK as examples.

In the domestic market, the company has served tens of thousands of end-users in the medical and health field, including hospitals, biotechnology enterprises, universities & colleges, scientific research institutions, centers for disease control, plasma stations, and testing institutions. Well-known customers in China include the Chinese PLA General Hospital (301 Hospital), Shanghai Ruijin Hospital, Wuxi Apptec, Shanghai Fudan University, China Center for Disease Control and Prevention, Hualan Biological, Hengrui Pharmaceutical, and Fosun Pharmaceutical.

Since going public, Haier Biomedical has been releasing social responsibility reports regularly every year. Bearing in mind the vision of social responsibility - Intelligence Enlightens Life for a Shared Future, the Company has set up a social responsibility model with "LIFE (Leadership, Integrity, Future, and Ecosystem)" as the core and the four major fields- Leadership, Integrity, Future, and Ecosystem as the focus to give back to the community with practical actions. The Company adheres to board member diversity all the time in order to gain opinions from different perspectives and promote the sustainable and sound development of the Company. In 2022, 36% of the members of Haier Biomedical’s board of directors are female. In addition, Haier Biomedical has established a whole-process quality control system ranging from research and development to procurement, manufacturing, and services to practice our quality philosophy of “Respecting Life”. Based on the management philosophy of "non-discrimination, diversity, and equal opportunities" and the Rendanheyi management model, the Company has established an open and three-dimensional talent acquisition system. In 2022, 778 talents joined the Company as attracted by the dynamic innovation and entrepreneurship platform provided by us for every employee. Overseas, the Company keeps cultivating localized operations, including the localized operation of the overseas operation bases and training centers and the localized operation of the local product distribution, installation, maintenance, and other after-sales services, which not only improves the knowledge and skills of the local people but also brings new job opportunities to some less developed regions. The Company has also established carbon reduction paths involving the whole life cycle, including green building, green design, green procurement, green manufacturing, green logistics, and green office, to empower carbon reduction practices through technological innovation and continuously lead the green transformation development of the industry. In 2022, Haier Biomedical generated 1.489 million KWh of electricity through photovoltaic power generation equipment, equivalent to reducing carbon emissions by 865.69 tons. Haier Biomedical’s solar vaccine refrigerator series products and solutions can reduce carbon emissions by 109,500 tons per year, which is a neutralization equivalent of 4500 mus of mature trees.

Haier - Biomedical Heating Cabinet - Brochure

Contact supplier